Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed With Plasmodium Falciparum - Trial NCT06040346
Access comprehensive clinical trial information for NCT06040346 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd and is currently Not yet recruiting. The study focuses on Malaria. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Timeline & Enrollment
Phase 2
Dec 15, 2023
Sep 09, 2024
Primary Outcome
The Number of participants with Drug-related SAE, All-cause SAE, Drug-related AESI, All-cause AESI.,The Number of Participants discontinuation/ withdrawals due to AE
Summary
This phase 2a open-label study to assess Meplazumab in adult patients diagnosed with
 Plasmodium falciparum
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06040346
Non-Device Trial